Jeremy Bender - Nov 15, 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Chief Executive Officer, Director
Signature
/s/ Charles N. York II, Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Nov 15, 2022
Transactions value $
-$32,469
Form type
4
Date filed
11/17/2022, 04:33 PM
Previous filing
Nov 3, 2022
Next filing
Nov 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Options Exercise +3.56K +0.29% 1.22M Nov 15, 2022 Direct F1
transaction DAWN Common Stock Sale -$32.5K -1.51K -0.12% $21.46 1.22M Nov 16, 2022 Direct F2
holding DAWN Common Stock 282K Nov 15, 2022 See Footnote F3
holding DAWN Common Stock 282K Nov 15, 2022 See Footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Restricted Stock Units Options Exercise $0 -3.56K -7.69% $0.00 42.8K Nov 15, 2022 Common Stock 3.56K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
F3 Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
F4 Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.
F5 The RSUs will vest as to 1/12 of the total award in quarterly installments on February 15th, May 15th, August 15th, and November 15th, subject to the Reporting Person's continued service to the Issuer on each vesting date.